Financhill
Buy
53

OCX Quote, Financials, Valuation and Earnings

Last price:
$2.60
Seasonality move :
-6.1%
Day range:
$2.57 - $2.79
52-week range:
$1.92 - $3.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
39.98x
P/B ratio:
4.56x
Volume:
51.7K
Avg. volume:
74.1K
1-year change:
-14.33%
Market cap:
$44.3M
Revenue:
$1.5M
EPS (TTM):
-$4.54

Analysts' Opinion

  • Consensus Rating
    OncoCyte has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $4.13, OncoCyte has an estimated upside of 56.84% from its current price of $2.63.
  • Price Target Downside
    According to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $2.63.

Fair Value

  • According to the consensus of 2 analysts, OncoCyte has 56.84% upside to fair value with a price target of $4.13 per share.

OCX vs. S&P 500

  • Over the past 5 trading days, OncoCyte has overperformed the S&P 500 by 12.37% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • OncoCyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • OncoCyte revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter OncoCyte reported revenues of $115K.

Earnings Growth

  • OncoCyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter OncoCyte reported earnings per share of -$0.98.
Enterprise value:
40.9M
EV / Invested capital:
--
Price / LTM sales:
39.98x
EV / EBIT:
--
EV / Revenue:
57.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$115K
Return On Assets:
-57.93%
Net Income Margin (TTM):
-6085.19%
Return On Equity:
-211.42%
Return On Invested Capital:
-211.42%
Operating Margin:
-5543.48%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -$1.3M $1.5M $709K $429K $115K
Gross Profit $2.6M $503K -$115K $248K $50K
Operating Income -$13M -$23.4M -$22.9M -$5.1M -$6.4M
EBITDA -$28.6M -$1.9M -$41.8M -$6M -$13.1M
Diluted EPS -$13.10 -$9.51 -$4.54 -$0.81 -$0.98
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $12M $47.6M $36.6M $16.9M $4.8M
Total Assets $57.8M $168.3M $157.3M $81.6M $70.2M
Current Liabilities $8.9M $13.4M $13M $8M $9.1M
Total Liabilities $23.1M $69M $80.5M $44M $60.5M
Total Equity $34.6M $99.3M $76.9M $37.6M $9.7M
Total Debt $4.1M $1.7M -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$43M -$28.5M -$19.8M -$3.8M -$5.6M
Cash From Investing -$3.9M -$1.8M -$199K $214K -$87K
Cash From Financing $35.6M $12.1M $9.6M -$30K -$255K
Free Cash Flow -$46.9M -$29.4M -$20.3M -$3.8M -$5.6M
OCX
Sector
Market Cap
$44.3M
$43.6M
Price % of 52-Week High
75.58%
47.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
-14.33%
-34.6%
Beta (5-Year)
0.903
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $2.58
200-day SMA
Sell
Level $2.77
Bollinger Bands (100)
Buy
Level 2.17 - 2.93
Chaikin Money Flow
Sell
Level -104.1M
20-day SMA
Buy
Level $2.27
Relative Strength Index (RSI14)
Buy
Level 63.38
ADX Line
Buy
Level 35.01
Williams %R
Neutral
Level -24.301
50-day SMA
Buy
Level $2.24
MACD (12, 26)
Buy
Level 0.13
25-day Aroon Oscillator
Buy
Level 80
On Balance Volume
Neutral
Level 101.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-6.2078)
Sell
CA Score (Annual)
Level (-2.596)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (5.4569)
Buy
Piotroski F Score (Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)

Revenue Forecast

Earnings per Share Forecast

Company Profile

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

Stock Forecast FAQ

In the current month, OCX has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The OCX average analyst price target in the past 3 months is $4.13.

  • Where Will OncoCyte Stock Be In 1 Year?

    According to analysts, the consensus estimate is that OncoCyte share price will rise to $4.13 per share over the next 12 months.

  • What Do Analysts Say About OncoCyte?

    Analysts are divided on their view about OncoCyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OncoCyte is a Sell and believe this share price will drop from its current level to $4.00.

  • What Is OncoCyte's Price Target?

    The price target for OncoCyte over the next 1-year time period is forecast to be $4.13 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is OCX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for OncoCyte is a Hold. 2 of 2 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of OCX?

    You can purchase shares of OncoCyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OncoCyte shares.

  • What Is The OncoCyte Share Price Today?

    OncoCyte was last trading at $2.60 per share. This represents the most recent stock quote for OncoCyte. Yesterday, OncoCyte closed at $2.63 per share.

  • How To Buy OncoCyte Stock Online?

    In order to purchase OncoCyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock